|
||
| |||||||
|
A Shift in Cancer Immunotherapy Strategies? Executive Summary: "A Shift in Cancer Immunotherapy Strategies?" is the most extensive description and analysis of industry activities utilizing immunotherapeutic strategies for combating cancer. BioSeeker Group has analyzed more than 650 industry related cancer immunotherapy R&D projects (more 425 clinical trials of which 60 are in phase III) in order to elucidate changes in strategies for cancer immunotherapy. Conference information from the latest meeting held by the American Society of Clinical Oncology, the American Association Cancer Research and the American Society of Hematology is also included in this extensive analysis. This 500+ page report is a close to complete description of the ongoing efforts to develop innovative immunotherapies for the treatment of cancer. The report identifies trends, describes and analyzes strategic shifts made by the industry. It also serves as a guide and a foundation for your needs of information structure. BioSeeker Group has structured the contents of this report into several well-defined therapeutic concepts. This includes major therapeutic strategies such as monoclonal antibodies, anti-idiotypic antibodies, tumor antigens, cellular vaccines, gene therapy, immunostimulatory drugs and other biological drugs. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment. The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough succes. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, a drug that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other immune-based therapies that have already reached the market is Zevailn, Bexxar, Campath, OncoVax and Erbitux. Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing pieces. The efficacy of immunotherapy should and could be improved. More simple protocols are now being exchanged for more sophisticated ones, and novel solutions are continuing to emerge. The report also evaluates the latest advancements in cancer immunotherapy as well as describes key company activities. BioSeeker Group is monitoring a large number of companies working in this field enabling highly updated analysis. In a coming report entitled "Immunotherapies Impact on the Cancer Market", BioSeeker Group will discuss late stage immunotherapy drugs and their effect on the market. About Industry Activity Reports - The Most Valuable Trend Analytical Report Available BioSeeker Group has recognized the need for deeper analytical reports. Our Industry Activity Reports analyze activities with large impact on R&D and market trends. Our Industry Activity Reports, focus on different segments of the industry and follows and identifies important activities. It is almost impossible to keep up with the enormous amount of information that we continuously are exposed to. It gets worse when you want to structure and analyse it. Through the continuous surveillance of more than 10 000 life science companies worldwide, BioSeeker Group analyses activities in biotechnology and pharmaceutical industry. Sophisticated information management in combination with highly educated analysts with extensive experience in business intelligence builds a strong platform for producing valuable analytical documents. These reports will allow you to: > identify and follow trends and future insights > plan strategically > identify key breakthroughs important for your company > get smarter in a tougher competition > exploit our independent analysis > track cutting edge companies, therapies and new technologies > save significant time in identifying your partners & competitor. Size: 560 pages Release date: Jul 25, 2003 Publisher: BioSeeker 2003 To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker_2003.html#a459
|
|
|
